Zebrafish Screening

Zebrafish screening is a powerful, high-throughput in vivo phenotypic screening technology for preclinical drug discovery, leveraging the zebrafish's unique biological advantages—90% genetic homology with humans, rapid embryonic development, transparent larvae, and high reproductive capacity—to enable real-time, whole-organism assessment of drug efficacy, toxicity, and mechanism of action. As a premier preclinical screening platform, it bridges in vitro cell-based assays and mammalian animal models, providing physiologically relevant in vivo data for hit validation, lead optimization, and safety evaluation.

Fig 1. Zebrafish served as a rapid means for phenotype-based high-throughput drug screening.¹

PharmaAnalytica, a core brand of STEMart, offers customized zebrafish screening services for global biotech and pharmaceutical clients, integrating standardized zebrafish models, high-throughput imaging systems, and professional phenotypic analysis to accelerate the translation of drug candidates from early discovery to preclinical development.

Our zebrafish screening platform covers a full spectrum of disease models and screening applications, including oncology, cardiovascular disease, neurological disorders, metabolic diseases, and anti-infective drug development, as well as acute toxicity, developmental toxicity, and off-target effect assessment. By combining chemical genetic screening, CRISPR/Cas9 gene-edited zebrafish models, and high-content phenotypic analysis, we enable efficient identification of lead compounds with in vivo activity and favorable safety profiles, significantly reducing the attrition rate of drug candidates in late-stage preclinical and clinical trials.

Standard Zebrafish Screening Workflow

Our standardized zebrafish screening service follows a rigorous 4-phase workflow, ensuring reliable, physiologically relevant in vivo data for drug discovery:

1. Model Customization & Preparation: Select or construct disease-specific zebrafish models (wild-type, transgenic, gene-edited) based on client research goals (e.g., VEGF transgenic zebrafish for anti-angiogenic drug screening, tp53 mutant zebrafish for oncology research). Standardize embryo collection and culture to ensure synchronous developmental stages for screening.
2. Drug Treatment & Incubation: Administer test compounds (hit/lead molecules) to zebrafish embryos/larvae via microinjection, immersion, or oral gavage at gradient concentrations, with vehicle and positive control groups set up in parallel. Incubate samples in the incubator under optimized temperature and light conditions for a predefined period (24–120 hpf, hours post fertilization).
3. High-Throughput Phenotypic Imaging & Analysis: Perform automated imaging of drug-treated zebrafish and capture phenotypic and molecular markers (e.g., fluorescent reporters for angiogenesis). Use AI-driven software to quantify phenotypic parameters and identify compounds with desired activity (e.g., anti-tumor, cardioprotective) or assess toxic effects (e.g., developmental malformation, lethality).
4. Hit Validation & Mechanistic Analysis: Conduct secondary validation of primary active compounds with independent replicate experiments and concentration-response analysis. Use electrophoresis system for molecular genotyping and gene expression analysis, combined with pathway enrichment analysis (e.g., KEGG, GO) to elucidate the in vivo mechanism of drug action, and provide a comprehensive screening report with phenotypic, quantitative, and molecular data.

PharmaAnalytica's Technology Platform

Advantages of PharmaAnalytica's Zebrafish Screening Services

Backed by STEMart's strong R&D capabilities and PharmaAnalytica's professional preclinical research platform, our zebrafish screening services provide a reliable in vivo screening solution for global drug discovery clients, accelerating the identification of high-quality lead compounds and reducing the time and cost of preclinical drug development.

High-Throughput & Cost-Effective

Enables parallel screening of thousands of compounds in a single experiment with low per-sample cost, far more efficient than mammalian animal models (e.g., mice, rats).

In Vivo Physiological Relevance

Whole-organism screening captures drug effects on multiple organ systems and biological processes (e.g., metabolism, transport, off-target effects), providing more predictive data than in vitro cell assays.

Customized One-Stop Solutions

From disease model construction and compound screening to hit validation and mechanism analysis, we provide end-to-end services, supporting seamless translation from early hit discovery to preclinical safety and efficacy evaluation.

Professional Technical Team

Our team of zebrafish model experts, pharmacologists, and image analysts has extensive experience in preclinical drug discovery, providing customized experimental design and in-depth data interpretation for each project.

Backed by STEMart's strong R&D capabilities and PharmaAnalytica's professional preclinical research platform, our zebrafish screening services provide a reliable in vivo screening solution for global drug discovery clients, accelerating the identification of high-quality lead compounds and reducing the time and cost of preclinical drug development.